Pharma Merger
WILMINGTON, Del. – Directors are selling Dyax Corp. too cheaply through an unfair process to Shire Pharmaceuticals, for $37.30 a share or $5.9 billion, shareholders say in a class action in Delaware Chancery Court.
WILMINGTON, Del. – Directors are selling Dyax Corp. too cheaply through an unfair process to Shire Pharmaceuticals, for $37.30 a share or $5.9 billion, shareholders say in a class action in Delaware Chancery Court.